Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society

Neurology

Volumn 74, Issue 4, 2010, Pages 336-343

  Delgado, M R ^a   Hirtz, D ^b   Aisen, M ^c   Ashwal, S ^d   Fehlings, D L ^e   McLaughlin, J ^f   Morrison, L A ^g   Shrader, M W ^h   Tilton, A ⁱ   Vargus Adams, J ^j  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c United Cerebral Palsy Research Foundation   (United States)

^d LOMA LINDA UNIVERSITY   (United States)

^e HOLLAND BLOORVIEW KIDS REHABILITATION HOSPITAL   (Canada)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF NEW MEXICO   (United States)

^h THE CORE INSTITUTE   (United States)

ⁱ LOUISIANA STATE UNIVERSITY   (United States)

^j CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; DANTROLENE; DIAZEPAM; PHENOL; PLACEBO; TIZANIDINE;

AGITATION; ANOREXIA; ARTICLE; ASTHENIA; ATAXIA; BEDTIME DOSAGE; CATHETER COMPLICATION; CATHETER MALFUNCTION; CEREBRAL PALSY; CHILDHOOD DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPHONIA; DYSPNEA; ELECTROSTIMULATION; EVIDENCE BASED PRACTICE; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPERSALIVATION; HYPERTHERMIA; HYPOTENSION; INTERMETHOD COMPARISON; IRRITABILITY; LETHARGY; LIVER TOXICITY; MEDICAL SOCIETY; MENINGITIS; MONOTHERAPY; MOTOR PERFORMANCE; MUSCLE HYPOTONIA; MUSCLE WEAKNESS; OCCUPATIONAL THERAPY; PHYSIOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; SEDATION; SEIZURE; SEROMA; SIDE EFFECT; SOMNOLENCE; SPASTICITY; TOXICITY; VOMITING; WEAKNESS; WOUND INFECTION; XEROSTOMIA;

EID: 76749166415     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181cbcd2f     Document Type: Article

References (40)

1. Yeargin-Allsopp M, Van Naarden Braun K, Doernberg BA, Benedict RE, Kirby RS, Durkin MS. Prevalence of cerebral palsy in 8-year-old children in three areas of the United States in 2002: a multisite collaboration. Pediatrics 2008;121:547-554.
2. Paneth N, Hong T, Korzeniewski S. The descriptive epidemiology of cerebral palsy. Clin Perinatol 2006;33:251-267.
3. Boyle CA, Yeargin-Allsopp M, Doernberg NS, Holmgreen P, Murphy CC, Schendel DE. Prevalence of selected developmental disabilities in children 3-10 years of age: the Metropolitan Atlanta Developmental Disabilities Surveillance Program, 1991. MMWR CDC Surveill Summ 1996;45:1-14.
4. Ronan S, Gold JT. Nonoperative management of spastic-ity in children. Childs Nerv Syst 2007;23:943-956.
5. Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003;111:e89-e97.
6. Damiano DL, Quinlivan J, Owen BF, Shaffrey M, Abel MF. Spasticity versus strength in cerebral palsy: relationships among involuntary resistance, voluntary torque, and motor function. Eur J Neurol 2001;8 suppl 5:40-49.
7. Milla PJ, Jackson AD. A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1977;5:398-404.
8. Ward A. Long-term modification of spasticity. J Rehabil Med 2003;35:60-65.
9. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;192:540-542.
10. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67:206-207.
11. Nielsen JF, Sinkjaer T. A comparison of clinical and laboratory measures of spasticity. Mult Scler 1996;1:296-301.
12. Haugh AB, Pandyan AD, Johnson GR. A systematic review of the Tardieu Scale for the measurement of spastic-ity. Disabil Rehabil 2006;28:899-907.
13. Verrotti A, Greco R, Spalice A, Chiarelli F, Iannetti P. Pharmacotherapy of spasticity in children with cerebral palsy. Pediatr Neurol 2006;34:1-6.
14. Gracies JM, Elovic E, McGuire J, Simpson D. Traditional pharmacological treatments for spasticity: part I: local treatments. Muscle Nerve 1997;6 (suppl):S61-S91. (Pubitemid 128753039)
15. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity: part II: general and regional treatments. Muscle Nerve 1997;6 (suppl):S92-S120. (Pubitemid 128753040)
16. Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 1997;39:185-193.
17. Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pedi-atr 2000;137:331-337.
18. Lowe K, Novak I, Cusick A. Low-dose/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy. Dev Med Child Neurol 2006;48:170-175.
19. Wallen M, O'Flaherty SJ, Waugh MC. Functional outcomes of intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial. Arch Phys Med Rehabil 2007;88:1-10.
20. Kawamura A, Campbell K, Lam-Damji S, Fehlings D. A randomized controlled trial comparing botulinum toxin A dosage in the upper extremity of children with spasticity. Dev Med Child Neurol 2007;49:331-337.
21. Ackman JD, Russman BS, Thomas SS, et al. Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy. Dev Med Child Neurol 2005;47:620-627.
22. Moore AP, Ade-Hall RA, Smith CT, et al. Two-year placebo-controlled trial of botulinum toxin A for leg spas-ticity in cerebral palsy. Neurology 2008;71:122-128.
23. Bjornson K, Hays R, Graubert C, et al. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics 2007;120:49-58.
24. Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 1998;18:304-311.
25. Mall V, Heinen F, Siebel A, et al. Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev Med Child Neurol 2006;48:10-13.
26. Reddihough DS, King JA, Coleman GJ, et al. Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy. Dev Med Child Neurol 2002;44: 820-827.
27. Polak F, Morton R, Ward C, Wallace WA, Doderlein L, Siebel A. Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy. Dev Med Child Neurol 2002;44:551-555.
28. Ubhi T, Bhakta BB, Ives HL, Allgar V, Roussounis SH. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000;83:481-487.
29. Steenbeek D, Meester-Delver A, Becher JG, Lankhorst GJ. The effect of botulinum toxin type A treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: evaluation with goal attainment scaling. Clin Rehabil 2005;19:274-282.
30. Baker R, Jasinski M, Maciag-Tymecka I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002;44:666-675.
31. Kanovsky P, Bares M, Severa S, et al. Functional benefit of botulinum toxin (Dysport) in the treatment of dynamic equinus cerebral palsy spasticity: a prospective, multi-center, double-blind, placebo-controlled study. Ces A Slov Neurol Neurochir 2004;67:16-23.
32. Wenzel R, Jones D, Borrego JA. Comparing two botuli-num toxin type A formulations using manufacturers' product summaries. J Clin Pharm Ther 2007;32:387-402.
33. Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dys-port vs. Botox in primary palmar hyperhidrosis. Br J Der-matol 2003;149:1041-1045.
34. Simpson DM, Gracies JM, Graham HK, et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1691-1698.
35. Tilton AH. Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol 2004;11:58-65.
36. Mathew A, Mathew MC, Thomas M, Antonisamy B. The efficacy of diazepam in enhancing motor function in children with spastic cerebral palsy. J Trop Pediatr 2005;51: 109-113. (Pubitemid 40797012)
37. Engle HA. The effect of diazepam (Valium) in children with cerebral palsy: a double-blind study. Dev Med Child Neurol 1966;8:661-667.
38. Holt KS. The use of diazepam in childhood cerebral palsy. Report of a small study including electromyographic observations. Ann Phys Med 1964;suppl:16-24.
39. Hiller CJ, Mason JL, Jr. Therapeutic test of diazepam (va-lium) in cerebral palsy. J S C Med Assoc 1966;62:306-309.
40. Joynt RL, Leonard JA, Jr. Dantrolene sodium suspension in treatment of spastic cerebral palsy. Dev Med Child Neurol 1980;22:755-767.